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Abstract: In patients with diabetes, dysregulation of multiple glucoregulatory hormones
results in chronic hyperglycemia and an array of associated microvascular and macrovascular
complications. Optimization of glycemic control, both overall (glycosylated hemoglobin
[A1C]) and in the postprandial period, may reduce the risk of long-term vascular complications.
However, despite significant recent therapeutic advances, most patients with diabetes are
unable to attain and/or maintain normal or near-normal glycemia with insulin therapy alone.
Pramlintide, an analog of amylin, is the first in a new class of pharmaceutical agents and is
indicated as an adjunct to mealtime insulin for the treatment of patients with type 1 and type
2 diabetes. By mimicking the actions of the naturally occurring hormone amylin, pramlintide
complements insulin by regulating the appearance of glucose into the circulation after meals
via three primary mechanisms of action: slowing gastric emptying, suppressing inappropriate
post-meal glucagon secretion, and increasing satiety. In long-term clinical trials, adjunctive
pramlintide treatment resulted in improved postprandial glucose control and significantly
reduced A1C and body weight compared with insulin alone. The combination of insulin and
pramlintide may provide a more physiologically balanced approach to managing diabetes.
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Background
Diabetes results from the dysregulation of multiple glucoregulatory hormones that
normally act to maintain glucose homeostasis. These hormonal imbalances lead to
chronic hyperglycemia, which results in an array of microvascular complications
including retinopathy, nephropathy, and neuropathy. The Diabetes Control and
Complications Trial (DCCT 1993) and the UK Prospective Diabetes Study (UKPDS
1998) demonstrated that in patients with type 1 and type 2 diabetes, respectively,
improved overall glycemic control, as measured by glycosylated hemoglobin (A1C),
reduced the risk of development and progression of microvascular complications
(DCCT 1993; UKPDS 1998). Importantly, there does not appear to be a discernable
glycemic threshold, indicating that any reduction in A1C conveys clinical benefits
(UKPDS 1995, 1998; DCCT 1996). In addition to microvascular complications,
patients with diabetes also have at least a 2- to 10-fold greater risk for cardiovascular
disease than individuals without diabetes (Manson et al 1991; Stamler et al 1993;
ADA 2001). Cardiovascular disease is the leading cause of morbidity and mortality
in this patient population (Gaba et al 1999; ADA 2001). Recent evidence indicates
that improved overall glycemic control also reduces the risk for development of
cardiovascular disease in patients with type 1 diabetes (DCCT/EDIC 2005).
Unfortunately, despite intensive insulin therapy, many insulin-treated patients
are unable to achieve and maintain normal or near-normal glycemic control on a
long-term basis (DCCT 1993; UKPDS 1998). This is due to a number of limitations
of exogenously administered insulin, including weight gain and difficulty controlling
postprandial glucose excursions. Intensification of insulin therapy almost inevitably
results in weight gain (DCCT 1988; UKPDS 1998). This is not only a cosmetic
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deterrent to optimal therapy for many patients, but it has
been associated with various components of the metabolic
syndrome and increased cardiovascular risk (Purnell et al
1998; Purnell and Weyer 2003). A second important
limitation of insulin therapy is its frequent inability to
adequately control post-meal glucose excursions. Even
when used optimally, insulin injected subcutaneously does
not replicate normal postprandial insulin and amylin
secretion into the portal vein, frequently resulting in
persistent postprandial hyperglycemia (Hirsh 1999).
Investigation of additional therapies to optimize
glycemic control in patients with diabetes has led to the
development of pramlintide, an agent that mimics the actions
of the neuroendocrine hormone amylin. Amylin is co-
secreted with insulin from pancreatic beta cells in response
to nutrient intake (Young 1997; Kruger et al 1999) (Figure
1A). Insulin and amylin have complementary effects on
glucose metabolism. During the postprandial period, insulin
facilitates glucose disappearance from the circulation by
stimulating peripheral glucose uptake. Amylin regulates
glucose appearance into the circulation by three principal
mechanisms: regulation of gastric emptying (Young,
Gedulin, et al 1996), suppression of postprandial
glucagon secretion (Gedulin et al 1996), and regulation
of food intake (Bhavsar et al 1996). Both insulin and
amylin are absent in patients with type 1 diabetes and
deficient in later stages of type 2 diabetes (Fineman et al
1996; Young 1997; Kruger and Gloster 2004) (Figure
1B). Due to several physiochemical characteristics,
including insolubility and a propensity to aggregate,
native amylin cannot be formulated as a pharmaceutical
preparation.
Pramlintide, the active ingredient in SYMLIN
®
(pramlintide acetate) injection, is a soluble, non-aggregating,
synthetic analog of amylin. It mimics the glucoregulatory
effects of amylin, which collectively limit postprandial
glucose excursions (Young, Vine, et al 1996). Pramlintide
is indicated for use as an adjunct to mealtime insulin in
patients with type 1 and type 2 diabetes who are unable to
achieve glycemic goals with insulin therapy alone. Together
the complementary effects of insulin and pramlintide may
provide a more balanced approach to managing
hyperglycemia in patients with diabetes.
Pramlintide mechanisms of action
Clinical studies have demonstrated that pramlintide reduces
postprandial glucose concentrations through at least three
distinct mechanisms of action including modulation of
gastric emptying, prevention of abnormal postprandial
glucagon secretion, and increased satiety leading to a
reduction in caloric intake.
Gastric emptying in patients with diabetes is often
accelerated compared with healthy individuals (Schvarcz
et al 1997). This may, at least in part, be due to deficient
amylin secretion in response to meals. Since gastric
emptying is the rate-limiting step for glucose entering the
circulation, accelerated gastric emptying may exacerbate
postprandial glucose excursions in patients with diabetes.
Pramlintide slows gastric emptying, limiting the rate at
which nutrients are delivered from the stomach to the small
intestine and subsequently, the rate at which glucose enters
the circulation following meals. Pramlintide administered
to patients with diabetes slows gastric emptying of both solid
(Figure 2A) and liquid meals (Kong et al 1997, 1998). This
effect results in a decreased postprandial glucose excursion,
but does not affect the net absorption of nutrients.
Pramlintide also suppresses the inappropriately elevated
postprandial glucagon secretion that is often seen in patients
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Figure 1 (A) Amylin secretion mirrors insulin secretion in healthy subjects
(n=6) (adapted from Kruger et al 1999). (B) Amylin concentrations increase in
response to meals in healthy individuals (n=27). In patients with type 2 diabetes
(n=12), the amylin response is attenuated and in patients with type 1 diabetes
(n=190), it is virtually absent (adapted from Kruger and Gloster 2004).Vascular Health and Risk Management 2006:2(3) 205
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with diabetes. Glucagon, secreted from pancreatic alpha
cells, is a catabolic hormone that stimulates hepatic glucose
production in the fasting state to protect against
hypoglycemia. Normally, glucagon secretion is suppressed
after meals. However, in patients with type 1 and type 2
diabetes, postprandial glucagon secretion is abnormally
elevated. This inappropriate secretion of glucagon leads to
excess hepatic glucose production and is an important
contributor to postprandial hyperglycemia in patients with
diabetes (Unger et al 1970; Unger and Orci 1977). In clinical
studies of patients with type 1 and type 2 diabetes,
pramlintide administered prior to a meal significantly
reduced postprandial glucagon secretion compared with
placebo (Fineman, Koda, et al 2002; Fineman, Weyer, et al
2002) (Figure 2B).
Finally, pramlintide affects satiety, which leads to a
reduced caloric intake. A recent study in patients with type
2 diabetes and overweight subjects without diabetes
demonstrated that a single, preprandial, subcutaneous
injection of pramlintide reduced food intake by 16% to 23%
without changing mean meal duration (Chapman et al 2005).
Despite reduced caloric intake, pramlintide-treated subjects
reported satiety comparable with controls (Figure 2C).
Importantly, satiety was independent of nausea, which is
the most common side effect during initiation of pramlintide
therapy (Chapman et al 2005).
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Figure 2 Pramlintide mechanisms of action. (A) Pramlintide (30 µg or 60 µg) or placebo were injected subcutaneously 15 minutes prior to a solid meal in patients
with type 1 diabetes (n=11). Pramlintide significantly increased the gastric half-emptying compared to placebo (*indicates p<0.004) (adapted from Kong et al 1998).
(B) Patients with type 1 (n=9) and type 2 (n=12) diabetes were infused with either pramlintide (type 1 at 25 µg/h, type 2 at 100 µg/h) or placebo for 5 hours during a
SUSTACAL
® meal challenge test. Pramlintide significantly reduced postprandial plasma glucagon concentrations in patients with both type 1 and type 2 diabetes
compared with placebo control (p<0.05) (adapted from Fineman et al 2002). (C) Postprandial satiety quotients (5 h minus individual end of buffet VAS hunger ratings/
total energy intake) were calculated for patients with type 2 diabetes (n=11) receiving a single subcutaneous injection of either placebo or 120 µg pramlintide prior
to an ad libitum buffet meal. Pramlintide treatment significantly increased the postprandial satiety quotient (*indicates p=0.029) compared with placebo (adapted
from Chapman et al 2005).
Abbreviations: SE, standard error of mean.Vascular Health and Risk Management 2006:2(3) 206
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Clinical efficacy
Glycemic control
Pramlintide’s mechanisms of action collectively reduce
postprandial glucose concentrations. The effects of
pramlintide on the appearance of glucose in the circulation
during the postprandial period have been demonstrated in
several clinical studies. In patients with type 2 diabetes using
insulin lispro and type 1 subjects using either insulin lispro
or regular human insulin, pramlintide administered
immediately prior to a standardized meal significantly
reduced postprandial glucose excursions compared with
insulin therapy alone (Weyer et al 2003; Maggs et al 2004)
(Figure 3). Another study in patients with type 1 diabetes
using a continuous glucose monitoring system (CGMS)
demonstrated that following four weeks of pramlintide
treatment, glucose excursions were attenuated, resulting in
a reduction of ~2.5 hours per day spent in the hyperglycemic
range (>140 mg/dL) compared with baseline (Levetan et al
2003). Finally, in an open-label clinical practice study,
glucose fluctuations were examined in patients with type 1
and type 2 diabetes using self-monitored blood glucose
(SMBG) 7-point glucose profiles. Patients recorded blood
glucose values before and after the three major meals and
before bedtime on a single day at baseline while treated
with insulin alone, and again following 6 months of
pramlintide therapy as an adjunct to insulin. Six months of
pramlintide treatment significantly reduced postprandial
blood glucose excursions in both patients with type 1 and
type 2 diabetes (Guthrie et al 2005; Karl et al 2005) (Figure
4A, 4B). In each of these studies, improved postprandial
glucose control was observed in the context of significant
reductions in mealtime insulin (Levetan et al 2003; Weyer
et al 2003; Maggs et al 2004; Guthrie et al 2005; Karl et al
2005).
In placebo-controlled long-term clinical studies in
insulin-using patients with type 1 and type 2 diabetes,
pramlintide treatment also improved overall glycemic
control as measured by A1C (Ratner et al 2002, 2004;
Whitehouse et al 2002; Hollander et al 2003). Pramlintide
significantly reduced A1C over 26 weeks with mean
reductions of approximately 0.6% in patients with type 2
diabetes at the 120 µg dose (p<0.0001) and 0.4% in patients
with type 1 diabetes at 30 µg to 60 µg doses (p<0.0001)
(Figure 5A and 5B). Reductions in placebo-treated patients
were approximately 0.1% and 0.2% in type 1 and type 2
patients, respectively. In these studies, improved glycemic
control was achieved over 6 months with significant
reductions compared with placebo controls in total daily
insulin dose in both patients with type 1 (p<0.05) and type
2 (p<0.0001) diabetes (Figure 5), consistent with insulin
and pramlintide having complementary roles in postprandial
glucose homeostasis. A1C reductions were sustained up to
52 weeks in a placebo-controlled setting in both type 1 and
type 2 patients, as well as for an additional 52 weeks during
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Figure 3 Pramlintide reduces postprandial glucose concentrations. (A) Patients
with type 2 diabetes (n=19) were administered placebo or 120 µg pramlintide
and rapid-acting insulin lispro immediately prior to a meal. Patients with type 1
diabetes were administered placebo or 60 µg pramlintide with either (B) rapid
acting insulin lispro (n=21) or (C) regular human insulin (n=19) immediately
prior to a meal. In all cases, pramlintide significantly reduced postprandial
glucose concentrations in the postprandial period compared with placebo
controls (p<0.05) (adapted from Weyer et al 2003; Maggs et al 2004; and
SYMLIN 2005).
Abbreviations: SE, standard error of mean.Vascular Health and Risk Management 2006:2(3) 207
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an open-label extension (104 weeks total) in patients with
type 1 diabetes.
As mentioned previously, long-term, prospective clinical
trials have demonstrated that improvement of overall
glucose control (A1C) results in reduced risk of development
and progression of microvascular complications (DCCT
1993; UKPDS 1998). Long-term follow-up data from
patients with type 1 diabetes (DCCT/EDIC 2005) have
demonstrated that intensive treatment leading to improved
glycemic control also reduces long-term cardiovascular
complications. Clinical trials that address this relationship
in patients with type 2 diabetes are currently ongoing (Action
to Control Cardiovascular Risk in Diabetes [ACCORD] and
Veterans Affairs Diabetes Trial [VADT]) (Abraira et al 2003;
ACCORD 2006).
Recently, increasing emphasis has been placed on the
importance of controlling postprandial glucose excursions.
Postprandial glucose control is potentially important for at
least two reasons. First, it is an important component of
overall glycemic exposure (A1C). Studies have
demonstrated that at A1C levels approaching the American
Diabetes Association target of <7.0% (ADA 2005), the
relative contributions of postprandial glucose and fasting
glucose to overall glycemic control is approximately 70%
and 30%, respectively (Monnier et al 2003). Second,
independent of its effect on A1C, postprandial
hyperglycemia has been implicated in the development of
vascular diabetes complications. Brownlee and Hirsch
(2005) have postulated that A1C may be an incomplete
measure of glucose control and that glucose fluctuations
should also be taken into account when assessing a patient’s
risk of potential complications. Their hypothesis is based
on data from the DCCT which demonstrated that at similar
A1C levels, conventionally treated patients had an increased
risk of retinopathy compared with intensively treated
patients. This may have been due to reduced glucose
fluctuations in the intensively treated patients who were
treated with prandial insulin at each meal. A large body of
epidemiological data also supports the potential deleterious
effects of abnormal postprandial glucose excursions in
persons with impaired glucose tolerance and patients with
diabetes (Donahue et al 1987; Lowe et al 1997; DECODE
1999; de Vegt et al 1999; Rodriguez et al 1999; Tominaga
et al 1999). The mechanisms by which postprandial
hyperglycemia may increase the risk of diabetic
complications are emerging and the leading hypothesis
appears to be glucose-induced generation of oxidative stress
in the postprandial period (Brownlee 2005; Ceriello 2005;
Hirsch and Brownlee 2005).
Effects on weight
Weight gain is associated with the majority of
antihyperglycemic therapies and is often cited as one of the
primary reasons for patient non-compliance with insulin
therapy (Edelman and Weyer 2002). Excess body weight is
not only a cosmetic problem for patients, but also has
deleterious effects on glucose homeostasis due to its effects
on insulin resistance (Edelman and Weyer 2002).
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Figure 4 Pramlintide reduces diurnal glucose fluctuations. Patients with type 1
or type 2 diabetes in an open-label study self-monitored blood glucose for a 7
point glucose profile at baseline and following 6-months of pramlintide
treatment. Readings were recorded before and after the 3 major meals of the
day and before bedtime. (A) In patients with type 2 diabetes (n=166),
pramlintide 120 µg three times daily (TID) and twice daily (BID) significantly
reduced blood glucose concentrations following all three major meals
(*indicates p<0.05). (B) In patients with type 1 diabetes (n=265), pramlintide
30–60 µg TID and four times daily (QID) significantly reduced blood glucose
concentrations following breakfast and lunch (*indicates p<0.05) (Guthrie et al
2005; Karl et al 2005).
Abbreviations: SE, standard error of mean.Vascular Health and Risk Management 2006:2(3) 208
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Furthermore, obesity increases cardiovascular risk due to
effects on blood pressure and lipids (Alexander 2001; Vidal
2002) and also appears to have effects independent of these
established risk factors (Yan et al 2006). Weight control is
recognized as an important component of managing diabetes
and moderate reductions in weight (5% to 10%) often result
in improvements in glycemic control and cardiovascular
health, particularly in patients with type 2 diabetes
(Goldstein 1992; Williamson et al 2000; Vidal 2002).
Clinical studies have shown that improved glycemic
control in pramlintide-treated patients is not accompanied
by weight gain, and instead is associated with a sustained
and significant reduction in body weight (Ratner et al 2002,
2004; Whitehouse et al 2002; Hollander et al 2003).
Combined data from pramlintide clinical trials showed
significant (p<0.0001) reductions in body weight at 26
weeks of approximately 1.5 kg in patients with type 2
diabetes (Figure 5A) and 1.2 kg in patients with type 1
diabetes (Figure 5B) compared with an average gain of
0.2 kg to 0.5 kg, respectively, in placebo-treated patients. In
long-term trials, weight reductions were sustained up to 52
weeks in patients with both type 1 and type 2 diabetes.
Stratification of patients with type 2 diabetes based on
baseline body mass index (BMI) demonstrated that body
weight reductions were greatest in patients who were
overweight or obese, and that pramlintide was weight-
neutral in lean patients (Hollander et al 2004). Furthermore,
weight reduction in pramlintide treated patients occurred
without prescribed modification of diet or exercise routines
(Ratner et al 2002, 2004; Whitehouse et al 2002; Hollander
et al 2003).
One potential contributor to pramlintide-dependent
reductions in body weight may be pramlintide-induced
satiety. Chapman and colleagues (2005) observed that single
dose of pramlintide prior to a buffet meal reduced food intake
without affecting mean meal duration or macronutrient
preferences. Similar hunger and fullness ratings were
reported following pramlintide and placebo treatment,
despite significantly reduced caloric intake in pramlintide-
treated patients during the buffet meal. These data suggest
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that pramlintide exerts a satiety effect resulting in reduced
food intake.
Safety and tolerability
The primary adverse events associated with pramlintide
therapy apart from hypoglycemia were nausea, vomiting,
and anorexia (Ratner et al 2002, 2004; Whitehouse et al
2002; Hollander et al 2003). Gastrointestinal side effects
were more common in patients with type 1 diabetes, were
generally mild to moderate, and diminished over time.
Gradual dose-titration of pramlintide during the initiation
period (initial 4 weeks of treatment) effectively reduced the
incidence and severity of nausea in patients with type 1
diabetes (Edelman et al 2006). Importantly, the weight
reductions associated with pramlintide treatment appear to
be independent of pramlintide-induced nausea since
stratification of patients into groups that either did or did
not experience nausea during pramlintide treatment did not
reveal significant differences in body weight reductions
(Hollander et al 2003).
Although pramlintide itself does not cause
hypoglycemia, the addition of any antihyperglycemic agent
to an insulin regimen can increase the risk of severe insulin-
induced hypoglycemia. In the clinical development program,
pramlintide was studied in insulin-using patients with type
2 diabetes and patients with type 1 diabetes. To isolate the
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Figure 6 Annual event rate of medically assisted severe hypoglycemia in patients with type 1 and type 2 diabetes from the combined pivotal trials and an open-label
trial. (A) In blinded pivotal trials where there was no insulin reduction, the event rate for hypoglycemia in patients with type 2 diabetes treated with pramlintide was
higher in the first three months (n=292) compared with those treated with placebo (n=284). In the second three months of treatment, the event rate for patients
treated with pramlintide was less than placebo controls. In a subsequent open-label trial, in patients with type 2 diabetes (n=166) reduction of mealtime insulin and
titration of pramlintide during initiation further decreased the incidence of severe hypoglycemia. (B) In blinded pivotal trials of patients with type 1 diabetes where
there was no insulin reduction and no titration of pramlintide during initiation, the event rate of severe hypoglycemia in patients treated with pramlintide (n=716)
was increased in the first three months compared with placebo (n=538), but was reduced to similar levels as placebo in months 3 to 6. In a subsequent open label
study, titration of pramlintide during initiation combined with reduction of mealtime insulin further reduced the event rate of severe hypoglycemia in patients with
type 1 diabetes (n=265) (combined data adapted from Ratner et al 2002, 2004; Whitehouse et al 2002; Hollander et al 2003; Karl et al 2005; Guthrie et al 2005;
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effect of pramlintide during the initial clinical trials,
insulin dosages were not reduced when pramlintide was
introduced and an increase in severe hypoglycemia was
often observed. In subsequent clinical trials, mealtime
insulin was proactively reduced by 30% to 50% during
initiation of pramlintide treatment and, in patients with
type 1 diabetes, pramlintide dose was also progressively
escalated based on tolerability to nausea. Together these
measures reduced the incidence of severe hypoglycemia
in patients with both type 1 and type 2 diabetes (Edelman
et al 2006; SYMLIN 2005). Therefore, the risk of
hypoglycemia in pramlintide-treated patients is
manageable with careful titration of insulin and
pramlintide during initiation (Figure 6).
Pramlintide indications and dosing
The clinical data presented above culminated in the
current approved clinical indication for pramlintide as
an adjunct to mealtime insulin in patients with type 1 or
type 2 diabetes who have failed to reach desired glucose
control despite optimal insulin therapy. For patients with
type 2 diabetes, pramlintide can be used as an adjunct to
mealtime insulin with or without concurrent oral
sulfonylurea agents or metformin. Dosing of pramlintide
differs depending on whether the patient has type 1 or
type 2 diabetes. In patients with type 2 diabetes,
pramlintide should be initiated at a dose of 60 µg, and
subsequently increased to a maintenance dose of 120 µg
based on tolerability of nausea. In patients with type 1
diabetes, pramlintide should be initiated at a dose of 15 µg
and titrated upward in 15 µg increments to a maintenance
dose of 60 µg based on tolerability to nausea. If doses of
45 µg and 60 µg are not well-tolerated, a maintenance
dose of 30 µg can be used in patients with type 1 diabetes.
Pramlintide should always be administered in a separate
syringe and at a distinct injection site more than two
inches away from concomitant insulin injections
(SYMLIN 2005).
Pramlintide is used as an adjunct to insulin and has
been associated with an increased risk of insulin-induced
severe hypoglycemia, particularly in patients with type
1 diabetes. To minimize the risk of insulin-induced
hypoglycemia, all patients should reduce premeal insulin
by 50% upon initiation of pramlintide therapy, monitor
blood glucose frequently, and contact their healthcare
provider if symptoms of nausea and/or hypoglycemia are
persistent. Careful patient selection, patient instruction,
and insulin dose adjustments are critical for reducing the
risk of hypoglycemia (SYMLIN 2005).
Patients considering pramlintide therapy should have an
A1C <9%. Postprandial hyperglycemia is the major
contributor to overall hyperglycemia as patients approach a
more optimum A1C range. Pramlintide targets postprandial
glucose concentrations and should be considered as a
second-line therapy for those patients (type 2 or type 1
diabetes) who have an A1C <9%, but are unable to reach
desired A1C targets. Due to its effects on gastric emptying,
pramlintide should not be used in patients with diagnosed
gastroparesis or in patients that require drugs that stimulate
gastrointestinal motility. In addition, pramlintide should not
be used in patients with hypoglycemia unawareness
(SYMLIN 2005).
Conclusions
Pramlintide is a first-in-class amylinomimetic therapy for
insulin-using patients with diabetes that reduces
postprandial hyperglycemic excursions and improves
overall glycemic control with concomitant reductions in
weight and insulin use. There is accumulating evidence
that postprandial glucose fluctuations are a key
component to the management of overall glycemia and
an important predictor of cardiovascular risks associated
with diabetes. The actions of pramlintide to slow gastric
emptying, suppress inappropriately elevated postprandial
glucagon secretion, and reduce food intake act
collectively to limit postprandial glucose fluctuations and
improve overall glycemic control. The detrimental effects
of excess weight gain associated with many current
treatments for hyperglycemia and the cardiovascular risks
associated with obesity make weight control another
important aspect of therapeutic intervention in the
treatment of diabetes. Improvements in glycemic control
with pramlintide occur in the context of reductions in
weight, making it an additional therapeutic choice for
many insulin-using patients with type 1 or type 2 diabetes.
Together, the benefits offered by pramlintide may address
an important deficit in the treatment of diabetes. New
therapies may initiate a new phase of diabetes
management where multiple glucoregulatory agonists
will be used to more closely approximate normal glucose
homeostasis in patients with diabetes and may contribute
to prevention of the associated vascular complications
of the disease.Vascular Health and Risk Management 2006:2(3) 211
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